

<rss version="2.0"
     xmlns:content="http://purl.org/rss/1.0/modules/content/"
     xmlns:wfw="http://wellformedweb.org/CommentAPI/"
     xmlns:dc="http://purl.org/dc/elements/1.1/"
     xmlns:atom="http://www.w3.org/2005/Atom"
     xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
     xmlns:slash="http://purl.org/rss/1.0/modules/slash/">

    <channel>
        <title>PharmiWeb.com PwToday Stories</title>
        <atom:link href="https://www.pharmiweb.com/rss/pwtoday" rel="self" type="application/rss+xml" />
        <link>https://www.pharmiweb.com</link>
        <description>PharmiWeb.com | PWToday Stories about the Pharmaceutical industry</description>
        <lastBuildDate>Sun, 10 May 2026 04:59:49 +00:00</lastBuildDate>
        <language>en-GB</language>
        <sy:updatePeriod>hourly</sy:updatePeriod>
        <sy:updateFrequency>1</sy:updateFrequency>
                <item>
                    <title>UCB, Cancer Research UK and Cancer Research Horizons form oncology alliance</title>
                    <link>https://www.pharmiweb.com/pwtoday-story/ucb-cancer-research-uk-and-cancer-research-horizons-form-oncology-alliance</link>
                    <pubDate>Thu, 07 May 2026 08:36:43 +00:00</pubDate>
                    <guid isPermaLink="false">232916</guid>
                    <description><![CDATA[UCB, Cancer Research UK and Cancer Research Horizons have announced a new strategic alliance aimed at accelerating the development of novel cancer therapies. The collaboration will combine UCB’s expertise in antibody discovery and drug development with Cancer Research UK’s translational research capabilities and Cancer Research Horizons’ oncology innovation network.
The partnership is designed to speed the progression of promising oncology assets from early discovery through to clinical devel...]]></description>
                </item>
                <item>
                    <title>MSD (Merck) to acquire Terns Pharmaceuticals in USD 6.7 billion deal</title>
                    <link>https://www.pharmiweb.com/pwtoday-story/msd-merck-to-acquire-terns-pharmaceuticals-in-usd-67-billion-deal</link>
                    <pubDate>Wed, 06 May 2026 09:28:55 +00:00</pubDate>
                    <guid isPermaLink="false">232825</guid>
                    <description><![CDATA[MSD (Merck Sharp &amp;amp; Dohme)&amp;nbsp; has agreed to acquire Terns Pharmaceuticals in an all cash deal valued at approximately USD 6.7 billion, expanding its oncology and hematology pipeline. The acquisition gives Merck access to TERN 701, an investigational oral treatment for chronic myeloid leukemia currently in Phase 1 and 2 development. Merck said the programme has the potential to become a leading option for certain blood cancer patients and supports the company’s long term growth strategy...]]></description>
                </item>
                <item>
                    <title>UCB to acquire Candid Therapeutics</title>
                    <link>https://www.pharmiweb.com/pwtoday-story/ucb-to-acquire-candid-therapeutics</link>
                    <pubDate>Tue, 05 May 2026 10:25:47 +00:00</pubDate>
                    <guid isPermaLink="false">232711</guid>
                    <description><![CDATA[UCB, a global biopharmaceutical company, today (May 3rd) announced signing of a definitive agreement under which it would acquire Candid Therapeutics (Candid), a privately held clinical-stage biotechnology company redefining the treatment of autoimmune and inflammatory diseases through novel T-cell engagers (TCEs). This transaction supports UCB’s ambition to bring differentiated solutions to people with severe immune-mediated diseases by focusing on areas of high unmet need and it illustrates...]]></description>
                </item>
                <item>
                    <title>Serotonin link to tinnitus offers new insight for treatment balance</title>
                    <link>https://www.pharmiweb.com/pwtoday-story/serotonin-link-to-tinnitus-offers-new-insight-for-treatment-balance</link>
                    <pubDate>Thu, 30 Apr 2026 01:37:21 +00:00</pubDate>
                    <guid isPermaLink="false">232583</guid>
                    <description><![CDATA[Emerging research is shedding new light on the biological drivers of tinnitus, suggesting that serotonin, a neurotransmitter widely targeted in mental health treatments, may also influence the condition.
Scientists from Oregon Health and Science University and Anhui University have identified a specific brain circuit in animal models where increased serotonin activity directly affects auditory processing. Elevated levels of the neurotransmitter were associated with stronger tinnitus like resp...]]></description>
                </item>
                <item>
                    <title>Gilead and Arcellx advance CAR T partnership in multiple myeloma</title>
                    <link>https://www.pharmiweb.com/pwtoday-story/gilead-and-arcellx-advance-car-t-partnership-in-multiple-myeloma</link>
                    <pubDate>Wed, 29 Apr 2026 08:06:27 +00:00</pubDate>
                    <guid isPermaLink="false">232513</guid>
                    <description><![CDATA[Gilead Sciences and Arcellx continue to progress their collaboration focused on developing innovative cell therapies for multiple myeloma, with growing attention on their lead CAR T candidate. The partnership, originally established to accelerate next generation treatments, combines Arcellx’s ARC SparX platform with Gilead’s global development and commercial expertise.
The lead programme, anitocabtagene autoleucel, is being evaluated in clinical studies targeting patients with relapsed or ref...]]></description>
                </item>
                <item>
                    <title>Ligand to acquire XOMA Royalty in $739 million deal</title>
                    <link>https://www.pharmiweb.com/pwtoday-story/ligand-to-acquire-xoma-royalty-in-739-million-deal</link>
                    <pubDate>Tue, 28 Apr 2026 01:59:16 +00:00</pubDate>
                    <guid isPermaLink="false">232479</guid>
                    <description><![CDATA[Ligand Pharmaceuticals has announced plans to acquire XOMA Royalty in an all cash transaction valued at approximately $739 million. The move brings together two established players in the biotech royalty sector, both known for funding drug development in exchange for future revenue streams. 
The acquisition is expected to significantly expand Ligand’s portfolio, adding more than 120 assets and seven commercial products. Following completion, Ligand will oversee a portfolio exceeding 200 progr...]]></description>
                </item>
                <item>
                    <title>Sun Pharma to Acquire Organon in Transformational $11.75bn Deal</title>
                    <link>https://www.pharmiweb.com/pwtoday-story/sun-pharma-to-acquire-organon-in-transformational-1175bn-deal</link>
                    <pubDate>Tue, 28 Apr 2026 01:55:05 +00:00</pubDate>
                    <guid isPermaLink="false">232478</guid>
                    <description><![CDATA[Sun Pharmaceutical Industries and Organon &amp;amp; Co. have announced a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon in an all-cash transaction valued at approximately $11.75 billion.
The acquisition marks a significant strategic step for Sun Pharma, substantially expanding its global footprint and diversifying its portfolio beyond generics into higher-value segments. Organon brings a broad portfolio of more than 70 products spanning women’s health,...]]></description>
                </item>
                <item>
                    <title>Eli Lilly to acquire Ajax Therapeutics in $2.3bn oncology deal</title>
                    <link>https://www.pharmiweb.com/pwtoday-story/eli-lilly-to-acquire-ajax-therapeutics-in-23bn-oncology-deal</link>
                    <pubDate>Tue, 28 Apr 2026 01:50:31 +00:00</pubDate>
                    <guid isPermaLink="false">232477</guid>
                    <description><![CDATA[Eli Lilly has agreed to acquire Ajax Therapeutics in a deal worth up to $2.3 billion, strengthening its position in blood cancer research. The acquisition brings Ajax’s pipeline of next generation JAK inhibitors into Lilly’s portfolio, with a focus on rare conditions such as myelofibrosis.
At the centre of the agreement is Ajax’s lead candidate, a once daily oral therapy currently in early clinical development. It is designed to target patients who no longer respond to existing treatments, ad...]]></description>
                </item>
                <item>
                    <title>Centella compound shows promise against drug resistant bacteria</title>
                    <link>https://www.pharmiweb.com/pwtoday-story/centella-compound-shows-promise-against-drug-resistant-bacteria</link>
                    <pubDate>Wed, 22 Apr 2026 08:16:19 +00:00</pubDate>
                    <guid isPermaLink="false">232137</guid>
                    <description><![CDATA[Researchers at the University of Kent have identified a plant derived compound from Centella asiatica with potential to tackle antibiotic resistant infections. The ingredient, known as madecassic acid, is widely used in skincare but is now attracting attention for its antimicrobial properties.
Working with collaborators at University College London, scientists combined computational analysis with laboratory testing to explore how the compound affects harmful bacteria. The study found that it...]]></description>
                </item>
                <item>
                    <title>UCB to Acquire Neurona Therapeutics to Expand Epilepsy Pipeline with Regenerative Cell Therapy</title>
                    <link>https://www.pharmiweb.com/pwtoday-story/ucb-to-acquire-neurona-therapeutics-to-expand-epilepsy-pipeline-with-regenerative-cell-therapy</link>
                    <pubDate>Tue, 21 Apr 2026 10:05:51 +00:00</pubDate>
                    <guid isPermaLink="false">232041</guid>
                    <description><![CDATA[UCB has announced a definitive agreement to acquire Neurona Therapeutics in a deal valued at up to $1.15 billion, strengthening its position in epilepsy and advancing its move into regenerative medicine. The transaction includes an upfront payment of $650 million, with up to $500 million in milestone payments. 
The acquisition brings Neurona’s lead asset, NRTX-1001, into UCB’s portfolio. This investigational neuronal cell therapy is currently being evaluated in Phase I/II trials for drug-resi...]]></description>
                </item>
                <item>
                    <title>Eli Lilly to acquire Kelonia in major oncology expansion deal</title>
                    <link>https://www.pharmiweb.com/pwtoday-story/eli-lilly-to-acquire-kelonia-in-major-oncology-expansion-deal</link>
                    <pubDate>Tue, 21 Apr 2026 09:50:54 +00:00</pubDate>
                    <guid isPermaLink="false">232036</guid>
                    <description><![CDATA[Eli Lilly has agreed to acquire US based biotech Kelonia Therapeutics in a deal valued at up to 7 billion dollars, strengthening its position in cancer treatment innovation. The agreement includes an upfront payment with additional milestone based payments tied to clinical and commercial progress. 
Kelonia is developing next generation in vivo CAR T therapies, a novel approach that reprograms a patient’s immune cells directly inside the body to target cancer. This differs from traditional CAR...]]></description>
                </item>
                <item>
                    <title>GSK completes 35Pharma acquisition to strengthen cardiopulmonary pipeline</title>
                    <link>https://www.pharmiweb.com/pwtoday-story/gsk-completes-35pharma-acquisition-to-strengthen-cardiopulmonary-pipeline</link>
                    <pubDate>Thu, 16 Apr 2026 10:14:37 +00:00</pubDate>
                    <guid isPermaLink="false">231806</guid>
                    <description><![CDATA[GSK has completed its acquisition of Canadian biotech 35Pharma in a deal valued at 950 million dollars, marking a further step in its strategy to expand its specialty medicines pipeline. The clinical stage company focuses on protein based therapeutics, adding new scientific capabilities to GSK’s research portfolio. 
Central to the acquisition is HS235, an investigational therapy targeting pulmonary hypertension, a serious condition characterised by high blood pressure in the lungs and limited...]]></description>
                </item>
                <item>
                    <title>World Tumor Registry opens global breast cancer resource</title>
                    <link>https://www.pharmiweb.com/pwtoday-story/world-tumor-registry-opens-global-breast-cancer-resource</link>
                    <pubDate>Wed, 15 Apr 2026 09:14:02 +00:00</pubDate>
                    <guid isPermaLink="false">231726</guid>
                    <description><![CDATA[World Tumor Registry has launched its Breast Cancer Registry, an open access digital platform designed to support more accurate breast cancer diagnosis worldwide. The new resource brings together expert reviewed tumour cases, including both common and rare forms, and allows users to study high quality whole slide images alongside clinical, biomarker and molecular information. Led by Dr Edi Brogi of Memorial Sloan Kettering Cancer Center, the project already includes 100 fully annotated cases,...]]></description>
                </item>
                <item>
                    <title>Regeneron Expands into Radiopharma with Telix Collaboration</title>
                    <link>https://www.pharmiweb.com/pwtoday-story/regeneron-expands-into-radiopharma-with-telix-collaboration</link>
                    <pubDate>Tue, 14 Apr 2026 10:12:54 +00:00</pubDate>
                    <guid isPermaLink="false">231642</guid>
                    <description><![CDATA[egeneron has entered the fast growing radiopharmaceutical field through a new strategic collaboration with Telix, aiming to develop next generation targeted cancer therapies. The agreement focuses on combining Regeneron’s antibody expertise with Telix’s capabilities in radiopharma, a modality that delivers radiation directly to tumour cells.
Under the terms, the companies will jointly develop and commercialise multiple programmes, sharing costs and profits equally. Regeneron will provide an u...]]></description>
                </item>
    </channel>
</rss>